COR · 8-K · 20260805PR000032

Litigation and Legal Risk

Cencora, Inc. · 2026-08-05 · Importance 47 · Surprise 60

Cencora recorded a $102.0 million reduction in opioid liability in the third quarter after opioid litigation was dismissed. For the nine months ended June 30, 2026, the company also recorded an $86.8 million credit related to a derivative lawsuit settlement. Antitrust litigation settlements generated gains of $5.5 million in the quarter and $34.2 million year to date, involving lawsuits alleging that brand pharmaceutical manufacturers delayed or prevented generic-drug entry.

Key facts

• The Company recorded a $102.0 million reduction of opioid liability related to the dismissal of opioid litigation in the three months ended June 30, 2026 source
• The timing and amount of favorable and unfavorable settlements are unavailable and cannot be reasonably estimated source